Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy
Open Access
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 143, 1-9
Abstract
No abstract availableKeywords
Funding Information
- Swedish Research Council (2017-02413)
- Alzheimerfonden
- Åhlén-stiftelsen
- Stiftelsen Fondkistan
- Magnus Bergwalls stiftelse
- Stohnes Stiftelse
- Stiftelsen för Gamla Tjänarinnor
- Goljes stiftelse
This publication has 50 references indexed in Scilit:
- Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer's DiseasePLOS ONE, 2011
- Engaging neuroscience to advance translational research in brain barrier biologyNature Reviews Neuroscience, 2011
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic miceNeurobiology of Aging, 2009
- Amyloid‐β protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic miceThe FEBS Journal, 2009
- Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stainNature Protocols, 2006
- The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic miceNeurobiology of Aging, 2006
- Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid βThe Journal of Neuroscience, 2005
- Cerebral Hemorrhage After Passive Anti-Aβ ImmunotherapyScience, 2002
- The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formationNature Neuroscience, 2001